BCL2
ENSG00000171791
Target class
Ion channel
Chromosome
18
Approved drugs
1
Clinical candidates (approved and in development)
4
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- Yes
- Target name
- BCL2
- Gene name
- BCL2 apoptosis regulator
- Gene symbol
- BCL2
- Protein name
- Apoptosis regulator Bcl-2
- Bcl-2
- PPP1R50
- Gene biotype
- Protein coding
- Gene family
- Protein phosphatase 1 regulatory subunits|BCL2 family
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 51
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 49.69
- Tissue specificity (Gini)
- 0.469
- Tissue specificity (tau)
- 0.869
- KEGG gene identifiers
- hsa:596
- Protein interaction confidence
- 0.839151
- Protein interaction partners
- 271
- R-HSA-111447
- R-HSA-111453
- R-HSA-6785807
- R-HSA-844455
- R-HSA-9018519
- R-HSA-9634638
- R-HSA-9818030
- R-HSA-9824594
- End position
- 63320128
- Start position
- 63123346
- Chromosome
- 18
- Strand
- Reverse
- Mitochondrion outer membrane
- Single-pass membrane protein . Nucleus membrane
- Single-pass membrane protein . Endoplasmic reticulum membrane
- Single-pass membrane protein . Cytoplasm .
- Mitochondria
- PubMed 21358617
- PubMed 2250705
- Tissue specificity (tau)
- 0.868976
- Expression inequality (Gini)
- 0.469246
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 49.69
- Nerve - Tibial
- 23.76
- Thyroid
- 21.33
- Cervix - Ectocervix
- 17.92
- Uterus
- 17.47
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes49.69
- Nerve - Tibial23.76
- Thyroid21.33
- Cervix - Ectocervix17.92
- Uterus17.47
- Ovary15.53
- Cervix - Endocervix15.23
- Fallopian Tube12.88
- Spleen11.31
- Breast - Mammary Tissue11.27
- Adipose - Subcutaneous10.63
- Vagina10.21
- Artery - Coronary8.69
- Artery - Aorta8.19
- Esophagus - Muscularis8.09
- Adipose - Visceral (Omentum)8
- Esophagus - Gastroesophageal Junction7.91
- Prostate7.71
- Small Intestine - Terminal Ileum7.54
- Artery - Tibial7.35
- Colon - Sigmoid6.69
- Bladder6.45
- Pituitary5.81
- Skin - Not Sun Exposed (Suprapubic)5.19
- Skin - Sun Exposed (Lower leg)5.16
And 29 more, listed on the interactive page.
- GO:0000209
- GO:0006915
- GO:0006959
- GO:0006974
- GO:0008284
- GO:0008625
- GO:0009410
- GO:0009636
- GO:0010039
- GO:0010507
- GO:0030307
- GO:0030890
- GO:0032469
- GO:0034097
- GO:0035094
- GO:0042100
- GO:0043066
- GO:0043524
- GO:0050853
- GO:0051402
- GO:0051607
- GO:0051902
- GO:0051924
- GO:0070059
- GO:1902166
And 4 more, listed on the interactive page.
- GO:0005634
- GO:0005737
- GO:0005739
- GO:0005741
- GO:0005783
- GO:0005789
- GO:0016020
- GO:0031965
- GO:0032991
- GO:0046930
- GO:0002020
- GO:0005515
- GO:0015267
- GO:0016248
- GO:0031625
- GO:0042802
- GO:0043565
- GO:0046982
- GO:0051434
- GO:0060090
- GO:0140297
regulation of transcription factor activity
- cell-based: LTEA_HepaRG_BCL2is one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.
- cell-based: LTEA_HepaRG_BCL2is one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.
Biological samples
- HepaRG, cell line
Evidence source
Related records
Trials (868)
- 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
- A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
- A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
- A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
- A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
- A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
- A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
- A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML
- A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia
- A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
Drugs (7)
- APG-2575 Apoptosis regulator Bcl-2 inhibitor
- Navitoclax Apoptosis regulator Bcl-2 inhibitor
- Obatoclax Apoptosis regulator Bcl-2 inhibitor
- Obatoclax mesylate Apoptosis regulator Bcl-2 inhibitor
- Oblimersen Bcl-2 mRNA antisense inhibitor
- Oblimersen sodium Bcl-2 mRNA antisense inhibitor
- Venetoclax Apoptosis regulator Bcl-2 inhibitor